BAND enables agents across frameworks, clouds, enterprises, partners, and personal environments to communicate, collaborate, and operate together in real time

SAN FRANCISCO, April 23, 2026 — BAND, pioneering a new interaction layer for multi-agent systems, today announced its launch alongside a $17 million seed funding round with investment from Sierra Ventures, Hetz Ventures and Team8. The company is emerging from stealth to solve one of the most critical challenges in enterprise AI: enabling seamless communication and interaction between autonomous distributed agents across systems, teams, and organizations.

As enterprises begin deploying dozens or even hundreds of agents across engineering, security, and operations workflows, coordination between those agents is quickly becoming the next infrastructure challenge. By the end of 2026, 40% of enterprise applications will embed AI, yet 50% of agent deployments are predicted to fail due to insufficient runtime enforcement and multisystem interoperability and only 21% of companies currently have a mature governance and collaboration model to prevent it.

Currently, teams are forced to manually pass context between agents and maintain brittle coordination layers that were never designed for production-scale automation. What should be collaborative systems instead become fragmented siloes. In practice, this leaves developers and enterprise teams filling the gaps by manually passing information between agents, maintaining context across tools, and stitching together workflows that were never designed to function as a unified system.

BAND addresses these gaps by introducing a unified interaction layer that allows agents to discover each other, exchange context, delegate tasks and collaborate in real time, regardless of if they are custom agents written in leading frameworks like LangChain or CrewAI, third-party SaaS agents, coding agents such as Claude Code and Codex, or even personal AI assistants, such as OpenClaw. This critical shift transforms agents from isolated tools into coordinated participants in shared workflows.

“We’re entering the agentic economy, where millions of agents will need to collaborate across companies, platforms, and environments,” said Arick Goomanovsky, CEO and Co-Founder of BAND. “The challenge isn’t only building more agents, but getting them to work together in real time. BAND is building the infrastructure that makes that communication and interaction seamless, so agents can operate as part of a production-ready system, not isolated tools. This isn’t a nice-to-have, this is mission critical for the success of agent deployment in the enterprise.”

BAND enables developers to move from manually coordinating coding agents to running continuous, multi-agent interactions where planning, coding, testing, and monitoring agents operate together with shared context. R&D teams can build modular multi-agent architectures, encompassing agents running on different clouds or on-premise environments, instead of relying on brittle, monolithic systems. Enterprises can connect internal agents with those embedded in SaaS platforms and partner environments, creating cross-functional automation that was previously impossible. At the same time, personal agents can begin to interact with business agents or other users’ agents, pointing toward a future where individuals participate in a broader “internet of agents.”

Key capabilities include:

• A new architectural layer that provides shared infrastructure for multi-agent systems 
• Structured communication and delegation, preserving workflow context
• Cross-framework interoperability without rewriting agents
• Human-in-the-loop oversight for inspection, approval, and intervention
• Agent discovery and connection across internal and external environments

Additionally, built-in governance gives enterprises full visibility into agent interactions, monitors task delegation, and enforces authority boundaries, enabling secure and scalable multi-agent operations.

“Multi-agent systems are quickly becoming the foundation of modern software,” said Tim Guleri, Managing Director at Sierra Ventures. “Without a reliable and efficient way for agents to communicate, their potential is limited. BAND is building the missing layer that makes large-scale agent collaboration practical in all environments, in the enterprise and beyond.”

The $17 million seed round will expand BAND’s engineering team, accelerate product development, and grow its early design partner ecosystem across developers, enterprise platforms, and AI-native companies. Early adopters are already using BAND to build multi-agent systems in software development, enterprise automation, and advanced R&D.

About BAND
BAND builds enterprise-grade interaction infrastructure for distributed AI agents. Its platform enables real-time, multi-peer collaboration across agents and humans, while providing a runtime control plane that enforces policy, authority boundaries, and visibility across heterogeneous systems.

BAND supports developers, engineering teams, and enterprise platform leaders operating multi-agent ecosystems across internal systems, SaaS platforms, and partner environments.

BAND is backed by Team8, Hetz Ventures, and Sierra Ventures.

SOURCE BAND

Led by TLV Partners, Copperhelm introduces AI agents that investigate and remediate cloud threats in real time

TEL AVIV, Israel, April 23, 2026 — Copperhelm, a new cybersecurity company pioneering agentic cloud security, today announced its launch from stealth alongside $7 million in seed funding led by TLV Partners, with participation from toDay Ventures, ICON, and SaaS Ventures Israel. Notable Angel investors include Kfir Tishbi, Or Hiltch, Guy Zipori and Ephraim Yarmak. Already working with paying customers, including Fortune 500 enterprises, the company introduces a new model for cloud defense where AI agents replace manual workflows by continuously monitoring cloud environments, investigating threats, and executing real-time remediation, while keeping security teams in control.

Founded by Shimon Tolts, Eyar Zilberman, and Roman Labunsky, Copperhelm is built to address a growing gap in enterprise cloud security. The founding team brings deep experience from companies including Unity, McAfee, and RSA, with a track record of building cloud infrastructure and security products at scale. Their backgrounds include recognition as AWS Heroes, a CNCF Ambassador, a GitHub Star, and Y Combinator alumni.

AI has already transformed other domains, but it has not yet translated easily to cloud security. Cloud environments are highly complex and fragmented, making it difficult for AI to access and understand the full context needed to take action. Security teams cannot simply connect a general-purpose AI model to hundreds of cloud accounts and expect reliable results.

As AI agents take on more autonomous roles across industries, cloud security workflows have remained largely manual. Copperhelm changes that by bringing autonomy to cloud defense and enabling teams to operate at a fundamentally different scale. The company serves CISOs and security teams at large enterprises, offering a new model where humans remain in control and AI agents perform the heavy lifting. By continuously monitoring the environment, investigating threats, and remediating vulnerabilities, Copperhelm enables teams to focus on the most critical risks while significantly increasing operational efficiency.

Copperhelm solves this challenge with its Context Lake, a real-time decision layer for cloud security that structures and connects cloud data across environments, enabling AI agents to accurately investigate and remediate risk. Unlike general-purpose AI tools, Copperhelm is purpose-built for cloud environments, operating across hundreds of accounts with the scale and connectivity required to take meaningful action. This enables its agents to continuously analyze infrastructure, validate real risk, and execute remediation with high confidence.

Built on its Context Lake, Copperhelm deploys purpose-built AI agents that act as an extension of the security team. These agents continuously analyze infrastructure, investigate real risk, and execute remediation actions in real time, enabling organizations to move from alert to resolution without traditional manual handoffs. With CopperHelm’s agentic approach, one Fortune 500 company transformed 6 million of raw findings into a few hundreds evidence-backed shortlist of validated risks their teams could actually remediate, cutting engineering toil and accelerating action on the exposures that mattered most.

“Engineering teams got AI years ago; security was left behind doing manual work,” said Shimon Tolts, CEO and Co-Founder of Copperhelm. “Copperhelm finally brings true AI to cloud security. It’s like instantly adding twenty senior engineers to your team.”

The platform includes specialized agents focused on network analysis, system behavior, adversary simulation, and automated remediation. These agents connect directly to live workloads, inspect active processes and container images, map cloud network topology, and deploy targeted protections such as WAF rules to mitigate threats without downtime.

“Applying AI to cloud security requires deep architectural expertise, not just generic models with integrations,” said Rona Segev, Co-Founder and Managing Partner at TLV Partners. “Shimon, Eyar, and Roman are true cloud veterans and the right team to bring autonomous AI into this space and shape the future of cloud defense.”

The $7 million in funding will be used to accelerate product development, expand go-to-market efforts, and scale Copperhelm’s engineering team. As part of today’s announcement, Shay Michel, Managing Partner at Merlin Ventures, will join Copperhelm’s board of directors.

About Copperhelm
Copperhelm is the leader in agentic cloud security, helping enterprises defend their cloud environments with AI agents that understand infrastructure as deeply as experienced engineers. By combining autonomous investigation and remediation with a real-time contextual understanding of cloud environments, Copperhelm enables security teams to eliminate manual work, reduce risk, and operate at an unprecedented scale. Founded by cloud and security veterans from Unity, McAfee, and RSA, the team includes recognized industry leaders, with CEO Shimon Tolts named an AWS Hero and CNCF Ambassador, and CPO Eyar Zilberman recognized as a GitHub Star. Headquartered in Tel Aviv, Copperhelm serves global enterprises. Learn more at www.copperhelm.com.

Media:
Angelique Faul
513-633-0897
[email protected]

SOURCE Copperhelm

FORT COLLINS, Colo., April 23, 2026 — Healthy Smart Mart™, a leader in unattended retail, has announced the expansion of its micro market business model, positioning it as a premier solution for entrepreneurs seeking sustainable passive income. As the global economy shifts toward automated wealth generation, the company’s systems offer a high-margin alternative to traditional vending and labor-intensive franchises.

The announcement comes as investors seek assets requiring minimal time. Healthy Smart Mart™ micro markets transform workplace break rooms into modern, cashless convenience stores operating 24/7. Unlike legacy vending, these open-market designs enable fresh, healthy food options that cater to employee demand for workplace wellness.

The Evolution of Passive Income

For decades, passive income was limited to real estate or stocks. However, automated micro-retail has introduced a third pillar. Healthy Smart Mart™ systems allow operators to generate revenue with as little as two hours of weekly maintenance. This efficiency is driven by proprietary technology that eliminates on-site staff, shielding owners from rising labor costs.

The scalability of the model is central to its appeal. Healthy Smart Mart™ strategically positions operators to dominate mid-sized locations with 100 to 500 employees. With millions of such locations across the United States, the company provides a path to secure prime placements, ensuring a stable, recurring revenue stream.

Advanced Technology and Operational Efficiency

At the heart of the model is a suite of payment solutions. The system offers multiple ways to complete transactions, including an all-in-one kiosk and a streamlined, app-based mobile option. This flexibility ensures a frictionless shopping experience for all users.

For the operator, this technology provides real-time sales data and automated inventory tracking. Restocking notifications are sent to the owner’s device, ensuring every trip is data-driven, reducing the time required to manage the business.

Capital Access Program

The company introduced a Capital Access Program to lower barriers to entry. This platform allows applicants to view pre-qualified financing options within minutes, covering essential startup costs. By streamlining access to capital, Healthy Smart Mart™ is enabling individuals to capitalize on the boom in automated convenience.

Learn more at https://healthysmartmart.com/.

Commitment to Corporate Wellness

In 2026, corporate wellness is a strategic necessity. Businesses are eager to host Healthy Smart Mart™ micro markets because they provide a valuable amenity at no cost to the employer. These markets improve morale and productivity by providing 24/7 access to nutritious meals, replacing uninspired vending selections with a curated, retail-like experience.

About Healthy Smart Mart™

Healthy Smart Mart™ offers a premier business opportunity for entrepreneurs ready to enter the micro market industry. By transforming traditional workplace break rooms into modern, cashless convenience stores, they help operators build profitable businesses. The company provides a proven model, innovative technology, and a unique funding program to ensure success.

Bill Way, CEO, is a recognized authority in the field and a number-one Wall Street Journal bestselling author. Most notably, his latest book, Micro Markets – Profit From The Automated Convenience Store BOOM! outlines the future of the vending and micro market industry and is the first and ONLY book in print on the subject. Mr. Way is available for interviews, which tend to be quite fun and extraordinary. For more information, please visit HealthySmartMart.com.

Contact Information

Name: Bill Way   
Email: [email protected]
Phone Number: (970) 222-8582

SOURCE Healthy Smart Mart™

Software-reconfigurable system delivers eight distinct configurations across a multi-vendor stack, now in active use by partners.

OXFORDSHIRE, United Kingdom, April 23, 2026 — TreQ has designed, built, and brought online its Open-Architecture Quantum (OAQ) Testbed, a fully operational, multi-vendor system now in active use. Part of Innovate UK’s Quantum Mission Pilot, the system operates independent processor, control, and software layers through well-defined interfaces. This enables:

• Reconfiguration and upgrades without rebuilding the stack
• Efficient system-level evaluation and comparison of potential builds
• Portability of solutions across configurations

“Open architecture quantum requires systems engineering to define interfaces, validate integration, and operate at system scale. It is much more than assembling components from multiple vendors,” said Mandy Birch, Founder and CEO of TreQ. “With the OAQ Testbed in operation, we’ve demonstrated that capital-efficient, flexible quantum infrastructure can be built and operated today.”

In just 3 months, from procurement to deployment within its purpose-built facility, TreQ brought online a complete multi-dimensional system that integrates products from across the industry. The team coordinated long-lead components from multiple suppliers and validated performance across multiple configurations.

Beginning with two options each for QPU, control hardware, and calibration software, the system supports eight computing configurations within the same three-rack footprint. The full system configuration can be switched via software, allowing performance assessment in different contexts without cycling or recabling the hardware.

This approach shifts quantum infrastructure from fixed configurations to adaptable architectures that incorporate best-in-class technologies. By defining core layers and integrating them through transparent interfaces, TreQ enables innovation throughout the stack and allows infrastructure investment to advance alongside a dynamic supply chain. Customers can evaluate, upgrade, and incorporate new technologies as they emerge, extending infrastructure lifetime, improving return on investment, and accelerating technical progress.

Open Architecture Quantum Validated

A world-first for open architecture, TreQ has delivered a full-stack system that enables direct evaluation and comparison within a single engineered environment. This demonstrates the viability of open-architecture approaches that rely on rigorous systems engineering rather than fixed integrations.

“The Novera QPU is designed for modularity, enabling ease of testing and integrating with new configurations and architectures. Validating the performance of the Novera QPU in different configurations within a multi-vendor architecture provides insight into system-level design and integration requirements for open architecture systems,” said Dr. Subodh Kulkarni, Rigetti CEO.

Interoperable at the Core

The OAQ Testbed’s engineered interfaces give innovators the freedom to build a stack from independently developed subsystems with low-friction, reliable interchangeability. A system orchestrator manages user requests across multiple levels of job abstraction and executes them on a selection of targets. Integrated calibration services continuously monitor and maintain system performance.

“Interoperability and autonomy are key to deployability. Running our autonomous calibration workflows on multiple configurations within a shared architecture makes it easier for users to pick the best system for their application, and achieve the best possible performance,” said Alex Shih, VP of Product at Q-CTRL.

Enabling Solution Portability

To ensure our clients’ solutions and intellectual property are portable between hardware systems, a TreQ-led consortium developed an open-source interface specification for vendor-interchangeable low-level integration. This specification has already been integrated into commercial offerings from Q-CTRL and Qruise, and demonstrated on Quantum Machines and Qblox control platforms. In collaboration with Oxford Ionics, an IonQ company, TreQ developed this specification to support multiple modalities, incorporating core operations for ion trap systems alongside superconducting processors from Rigetti and QuantWare housed in the same Maybell cryostat.

“The specification enables our AI-powered calibration technology to be deployed across more backends and increases the market reach of our solutions,” said Anurag Saha Roy, Chief Product Officer at Qruise.

Bringing Open Architecture to Market

TreQ now has a platform to efficiently expand its system offerings. This capability facilitates the evaluation of products from throughout the industry, while accelerating the incorporation of emerging offerings from a rapidly advancing supply chain.

Media Contact:
Megan Chalidis
+1 202.370.7473
[email protected]

SOURCE TreQ

• Novel bispecific antibody with a dual mechanism of action targeting anemia of inflammation in chronic kidney disease, autoimmune disease, and cancer
• Experienced leadership and advisory team with deep expertise in antibody engineering, red blood cell biology, and nephrology
• Seed financing led by Forty51 Ventures

BASEL, Switzerland, April 23, 2026 — Ferrosa Therapeutics AG (“FERROSA”), a Swiss biotechnology company developing a first-in-class bispecific antibody to treat anemia of inflammation, announced today a seed financing of USD 3.5 Million by founding investor Forty51 Ventures.

FERROSA’s lead program is a bispecific antibody designed to address key biological drivers of anemia of inflammation: cytokine-driven dysregulation of iron homeostasis that impairs erythropoiesis. The company’s proprietary dual-mechanism approach combines two complementary clinically validated pathways to restore effective red blood cell production and normalize iron availability.

Anemia of inflammation is a prevalent comorbidity in patients with chronic kidney disease, autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease, and many cancers. Existing treatments – including erythropoiesis-stimulating agents, intravenous iron, and blood transfusions – address symptoms rather than the underlying biology and carry safety risks. There is a substantial unmet medical need for therapies that mechanistically correct iron restriction and restore effective erythropoiesis.

With the current financing, FERROSA will advance its preclinical program through antibody generation, bispecific engineering, and in vivo proof-of-concept studies in disease-relevant animal models.

The company appointed co-founder Martin Stern, MD as the Chief Executive Officer. Martin Stern is a physician-scientist and board-certified hematologist with more than 25 years of combined academic and industry experience. He previously served as Chief Medical Officer at Numab Therapeutics, where he led clinical development of multispecific antibodies in oncology and immunology, and as CMO at Affivant Sciences. Earlier in his career, he held senior positions at Roche Pharma Research and Early Development (pRED). Prior to that he was clinically active as a hematologist for more than a decade.

Martin Stern commented: “Anemia of inflammation remains one of the most prevalent yet inadequately treated complications across chronic diseases. Our bispecific approach has the potential to change how clinicians manage this condition – moving beyond symptomatic support toward correction of the underlying pathophysiology. I am excited to build FERROSA and bring this differentiated therapy to patients who need it.”

FERROSA collaborates with leading experts in antibody engineering, red blood cell biology and nephrology. Dr. Beatriz Goyenechea, a recognized authority in antibody development and founder of StarBio International, serves as antibody development advisor. Prof. Stefano Rivella of the Children’s Hospital of Philadelphia advises on preclinical disease models. Prof. Beatrice Goilav, Professor of Pediatrics at the Albert Einstein College of Medicine and Montefiore Hospital, and a leading clinical researcher in chronic kidney disease, serves as KOL and Clinical Advisor to the company.

Forty51 Ventures is the seed investor of FERROSA and has been instrumental in the operational and financial set-up of the company. FERROSA was incorporated in Basel, Switzerland, a globally recognized hub for biotechnology and pharmaceutical innovation.

ABOUT FERROSA THERAPEUTICS

Ferrosa Therapeutics AG was founded in Basel, Switzerland by Forty51 Ventures in 2026. The company is developing a first-in-class bispecific antibody to treat anemia of inflammation across chronic kidney disease, autoimmune disease, and oncology. FERROSA’s dual-mechanism approach aims to restore iron homeostasis and effective erythropoiesis by addressing the cytokine-driven dysregulation at the heart of this condition. www.ferrosatx.com

ABOUT FORTY51 VENTURES

Forty51 Ventures is a venture capital firm with its core strategy focused on company formation in Biotech. Forty51 Ventures is a company builder leading first financing rounds of its growing portfolio of biotech companies www.forty51ventures.com

Contact:

Martin Stern
Chief Executive Officer
Ferrosa Therapeutics AG
[email protected] 
+41 79 818 06 32
www.ferrosatx.com

Logo: https://mma.prnewswire.com/media/2964149/Ferrosa_Therapeutics_Logo.jpg

SOURCE Ferrosa Therapeutics AG

Company partners with leading health plans, including Anthem and Health Net, to deliver a new model of care to millions of patients

KENMORE, Wash., April 23, 2026 — Zócalo Health, a tech-enabled, community-based primary care provider, today announced the close of $15 million in Series A funding, bringing the total raised to date to $22.75 million. The oversubscribed round was led by EO Ventures, with participation from Talipot and existing investors Vamos Ventures, Animo Ventures, Acumen America, Sorenson Ventures, BarronKent, and Kapor Center. The company will use the funds to accelerate nationwide expansion, scale its community-based workforce and deepen partnerships with health plans.

Funding comes as health plans face growing pressure to manage a small segment of members who drive a disproportionate share of healthcare costs. These patients, with complex medical, behavioral, and social needs, are historically difficult to engage in care. Zócalo Health is built specifically for this population, combining community-based care teams with virtual clinical services to drive sustained engagement, improve outcomes and reduce total cost of care within value-based frameworks.

“Zócalo Health has built a care model that performs in one of the most complex segments of healthcare,” said Roland Fryer, Founding Partner of EO Ventures and Harvard Professor of Economics. “It is demonstrating that community-based care, paired with the right operating model can scale and deliver meaningful results.”

Over the past year, Zócalo Health has demonstrated strong operating performance and early product-market fit. The company grew revenue approximately 4x year-over-year, expanded from two regional health plan partnerships in 2024 to more than a dozen in 2025, and is entering new markets across multiple states. The model has maintained high member retention, frequent monthly engagement and patient satisfaction scores that significantly exceed industry benchmarks.

A Model Built for Engagement and Retention

Zócalo Health is able to achieve outstanding outcomes for patients and health plans by organizing care around community health workers (CHWs), or promotoras de salud, who are embedded in the communities they serve. These teams are integrated with primary care providers, behavioral health clinicians, and care coordinators, enabling continuous engagement beyond traditional clinic settings. Notably, as patients have reported increased stress and anxiety, behavioral health has become a standout component of Zócalo Health’s model. Screening, care coordination and ongoing support are embedded into care delivery workflows, ensuring that behavioral health needs are addressed alongside medical and social needs from the start.

This integrated approach is designed specifically for members who are historically difficult to reach and retain. By focusing on proactive outreach, frequent touchpoints and trust-based relationships,  Zócalo Health successfully drives adherence and reduces avoidable utilization.

“We built Zócalo Health to consistently engage the patients the system misses,” said Erik Cardenas, Co-Founder and CEO. “Our model is designed around sustained engagement and outcomes. When you connect and engage RSS high-need members, you change both clinical outcomes and cost.”

Technology as a Scale Lever

As much as Zócalo Health has invested in developing personal relationships within communities, its sophisticated technology platform underlies operations for seamless care delivery. Its platform leverages AI to support and extend the capacity of frontline teams, allowing them to serve more members without sacrificing quality, while also improving how patients connect to care and community resources. The platform equips members with better visibility into their coverage and eligibility as well; it supports them alongside their CHWs in navigating Medicaid redetermination and evolving eligibility requirements.

Aligned with Health Plans, Built for Scale

Zócalo Health partners with Medicaid managed care organizations, including Anthem Blue Cross and Health Net, to deliver services aligned with broader state-led initiatives such as CalAIM across California. These programs are shaping a new blueprint for whole-person, community-based care that can be extended to other states over time.

The company’s growth has been driven by its ability to engage high-risk members, maintain strong retention, and operate with capital efficiency while expanding across geographies.

“Health plans are under pressure to deliver quality care for their most complex members, even as budgets tighten,” said Mariza Hardin, Co-Founder of Zócalo Health. “We’ve built a model that meets that challenge directly. This next phase is about scaling with discipline while maintaining both stellar performance and our deeply personal, community-driven touch.”

To learn more about Zócalo Health, the plans and segments it serves, and the services it offers, please visit www.zocalo.health.

About Zócalo Health

Zócalo Health is a community-based primary care provider delivering integrated medical, behavioral, and social care to underserved populations. The company partners with health plans to engage high-need members, improve outcomes, and reduce total cost of care through a model built on community health workers and technology-enabled care delivery.

SOURCE Zócalo Health

Die Finanzierungsrunde unter Führung von VP Capital und Oost NL beschleunigt die Einführung des Flaggschiffprodukts Repeltec und der patentierten wasserbasierten Löslichkeitstechnologie, während die EU ihre Pestizidvorschriften verschärft.

NIJMEGEN, Niederlande, 23. April 2026 — Affix Labs Group B.V., ein niederländisches Green-Chemtech-Startup, hat eine Finanzierungsrunde über 1 Million Euro unter Führung von VP Capital und Oost NL abgeschlossen. Das Unternehmen entwickelt ein wasserbasiertes Insektenschutzmittel, das die neurotoxischen Wirkstoffe ersetzt, die für die zunehmende Insektenresistenz verantwortlich sind. Mit dem neuen Kapital finanziert Affix Labs die europaweite Markteinführung.

Der Durchbruch: patentierte Löslichkeit und kontrollierte Freisetzung

Kern der Innovation ist eine Formulierungsmethode, mit der ölige, wasserunlösliche Wirkstoffe in wasserbasierten Systemen gelöst werden. Eine Schicht zur kontrollierten Freisetzung hält das Mittel bis zu zwölf Wochen wirksam. Das Flaggschiffprodukt Repeltec ist dermatologisch getestet und enthält keine neurotoxischen Verbindungen.

Sich verschärfende EU-Regulierung

Die EU verschärft ihre Vorschriften für chemische Pestizide. In Deutschland hat das Selbstbedienungsverbot 2025 eine breite Kategorie neurotoxischer Insektizide aus den offenen Regalen verdrängt, und andere Mitgliedstaaten ziehen mit ähnlichen Maßnahmen nach. Repeltec verfügt bereits über Wirkstoffzulassungen in Deutschland, Frankreich, Österreich und Norwegen.

Kommerzielle Expansion und B2B-Partnerschaften

Mit dem neuen Kapital baut Affix Labs seinen Vertrieb in Deutschland, Österreich, Frankreich und Norwegen aus. Großbritannien und Polen folgen. Neben den eigenen Verbraucherprodukten startet das Unternehmen ein White-Label-B2B-Modell unter dem Namen “Powered by Affix Labs”. FMCG-Unternehmen, Hotelleriebetriebe und Schädlingsbekämpfungshersteller können damit die Technologie in ihre eigenen Produktlinien integrieren.

Über Affix Labs

Affix Labs ist ein niederländisches Green-Chemtech-Startup, das die weltweite Abhängigkeit von Pestiziden verringert. Mit patentierter Löslichkeitstechnologie und Systemen zur kontrollierten Freisetzung schafft das Unternehmen langanhaltende, neurotoxinfreie Insektenbarrieren.

Pressekontakt

Tom Sam
[email protected]
www.affixlabs.com

Photo – https://mma.prnewswire.com/media/2964160/Affix_Labs.jpg
Logo – https://mma.prnewswire.com/media/2964159/Affix_Labs_Logo.jpg

Menée par VP Capital et Oost NL, cette levée de fonds accélère le déploiement du produit phare Repeltec et de la technologie brevetée de solubilité à base d’eau, dans un contexte de durcissement de la réglementation européenne sur les pesticides.

NIMÈGUE, Pays-Bas, 23 avril 2026 — Affix Labs Group B.V., une startup néerlandaise spécialisée dans la chimie verte (Green Chemtech), a bouclé une levée de fonds d’un million d’euros menée par VP Capital et Oost NL. L’entreprise développe un répulsif pour insectes à base d’eau qui remplace les substances actives neurotoxiques responsables de la résistance croissante des insectes. Le nouveau capital financera le déploiement européen.

La percée : solubilité brevetée et libération contrôlée

L’innovation centrale est une méthode de formulation qui permet de dissoudre dans l’eau des substances actives huileuses et insolubles. Une couche à libération contrôlée maintient l’efficacité du produit jusqu’à douze semaines. Le produit phare, Repeltec, est testé dermatologiquement et ne contient aucun composé neurotoxique.

Un cadre réglementaire européen qui se durcit

Les restrictions européennes sur les pesticides chimiques se durcissent. En Allemagne, l’interdiction du libre-service adoptée en 2025 a fait disparaître des rayons ouverts toute une catégorie d’insecticides neurotoxiques, et des mesures similaires sont en cours d’adoption dans d’autres États membres. Repeltec détient déjà des autorisations de substances actives en Allemagne, en France, en Autriche et en Norvège.

Expansion commerciale et partenariats B2B

Grâce au nouveau capital, Affix Labs étend sa distribution en Allemagne, en Autriche, en France et en Norvège. Le Royaume-Uni et la Pologne suivront. Parallèlement à ses gammes grand public, l’entreprise lance un modèle B2B en marque blanche sous le nom “Powered by Affix Labs”. Il permet aux entreprises FMCG, aux opérateurs hôteliers et aux fabricants de produits antiparasitaires d’intégrer la technologie dans leurs propres gammes.

À propos d’Affix Labs

Affix Labs est une startup néerlandaise Green Chemtech qui réduit la dépendance mondiale aux pesticides. Sa technologie de solubilité brevetée et ses systèmes à libération contrôlée créent des barrières anti-insectes durables et sans neurotoxiques.

Contact presse

Tom Sam
[email protected]
www.affixlabs.com

Photo – https://mma.prnewswire.com/media/2964160/Affix_Labs.jpg
Logo – https://mma.prnewswire.com/media/2964159/Affix_Labs_Logo.jpg

The funding round, led by VP Capital and Oost NL, accelerates the rollout of flagship product Repeltec and the company’s patented water-based solubility technology at a time when EU pesticide rules are tightening.

NIJMEGEN, Netherlands, April 23, 2026 — Affix Labs Group B.V., a Dutch Green Chemtech startup, has closed a €1 million funding round led by VP Capital and Oost NL. The company’s surface insect repellent replaces the neurotoxic active ingredients responsible for growing insect resistance with a water-based, controlled-release alternative. The new capital will fund the European rollout.

The Breakthrough: Patented Solubility and Controlled Release

The core innovation is a formulation method that dissolves oily, water-insoluble active ingredients into water-based systems. A controlled-release layer extends efficacy to 12 weeks. The flagship product, Repeltec, is dermatologically tested and contains no neurotoxic compounds.

A Tightening European Regulatory Environment

EU rules on chemical pesticides are tightening. Germany’s 2025 self-service ban pulled a broad category of neurotoxic insecticides from open retail shelves, and similar measures are now being adopted in other member states. Repeltec already holds active substance authorisations in Germany, France, Austria, and Norway.

Commercial Expansion and B2B Partnerships

With the new capital, Affix Labs is expanding distribution in Germany, Austria, France, and Norway, with the UK and Poland to follow. Alongside its consumer product lines, the company is launching a white-label B2B model under the name “Powered by Affix Labs”. FMCG companies, hospitality operators, and pest control manufacturers can use it to integrate the technology into their own product ranges.

About Affix Labs

Affix Labs is a Dutch Green Chemtech startup working to reduce global pesticide dependency. Its patented solubility technology and controlled-release systems create long-lasting, neurotoxic-free insect barriers.

Media Contact

Tom Sam
[email protected]
www.affixlabs.com

Photo – https://mma.prnewswire.com/media/2964160/Affix_Labs.jpg
Logo – https://mma.prnewswire.com/media/2964159/Affix_Labs_Logo.jpg